AUSTRALIAN TELETRIAL PROGRAM REACHES SIGNIFICANT MILESTONES IN TRIALS AND PARTICIPANTS From origins in Townsville to being national program across multiple disease states and populations
Filmed in Brisbane & Townsville, Queensland and Darwin, Northern Territory | November 2024
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
The program connects patients with researchers, medical professionals, and trial coordinators via video consultations and telehealth tools. This allows patients to receive treatment and follow-up care from their local healthcare providers, while still participating in high-quality clinical research.
Key Features of the Australian Teletrial Program:
- Remote Access to Trials: It facilitates the inclusion of patients from regional and remote areas who would otherwise have difficulty accessing clinical trials due to distance or travel constraints.
- Collaboration: The program involves partnerships between local healthcare providers, hospitals, research institutions, and trial sponsors. This collaborative model ensures that patients receive the best care and support throughout the trial process.
- Digital Health Technologies: Telehealth technologies, such as video conferencing, remote monitoring, and digital data collection, are used to manage patient care and ensure compliance with trial protocols.
- Widening Participation: It aims to diversify and increase the representation of regional and rural populations in clinical trials, which is important for trial results to include the broader population.
The Teletrial Program is part of a broader effort to improve the inclusivity and accessibility of medical research across Australia, ensuring that individuals, regardless of their location, have the opportunity to participate in cutting-edge clinical trials.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements:
- Being a proven program outside of oncology, with clinical specialties such as respiratory, cardiac, diabetes, sexual health, mental health filling a gap in service and equity.
- In regional, rural and remote places, with adults and paediatrics involved in the program, a higher than national average participation rate of clinical trials by First Nations peoples in satellite locations.
- Savings of time, money and distance for those patients to satellite sites.
- Having over a thousand participants in teletrials across the six jurisdictions.
- Established collaborative and supportive mechanism and network around education and training.
Australian Health Journal also spoke with Melanie Poxton, Assistant Director of Nursing at the program’s Queensland Regional Clinical Trials Coordinating Centre (QRCCC) in Townsville University Hospital, North Queensland and Heather Parker, the Northern Territory Australian Teletrial Program Manager with NT Health.
Produced in collaboration with the Australian Teletrial Program.
-
Awareness, diagnosis and treatment of Congenital Hypothyroidism
Australian Health Journal spoke to Associate Professor MIchelle Jack about congenital hypothyroidism and newborn screening and her concerns in the varying thresholds for across different states in Australia. Despite the existence of newborn screening programs since the 1970s, there is still controversy surrounding the appropriate screening levels. Congenital hypothyroidism, affecting about one in 3500 infants, can lead to severe intellectual and physical impairment if not diagnosed early. The condition is mainly caused by the thyroid gland’s failure to develop properly, resulting in insufficient thyroid hormone production.
-
Developing the next generation of medicines to target and enhance the microbiome
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years. -
State of Private Hospitals sector in Australia
During Mr Roff’s working career at APHA he has represented the private hospitals sector to nine different Federal Health Ministers and eight Prime Ministers. He believes the government should take steps to regulate the health insurance industry to protect consumers and ensure that Australians have access to affordable and comprehensive healthcare services.
